Pfizer Urges FDA To Prohibit Generic Exclusivity Transfer For Gabapentin

Allowing generic drug companies to use "first-to-file" exclusivity as a licensable asset will lead to "speculative" ANDA filings, Pfizer warned in a citizen petition seeking to block approval of Teva's generic version of gabapentin (Neurontin)